Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Very early onset inflammatory bowel disease Indication Strategy Report 2026: IL-10, Trials and Deals
3 August 2026
2026 Very early onset inflammatory bowel disease indication strategy covering epidemiology, IL-10 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Kindler epidermolysis bullosa Indication Strategy Report 2026: FERMT1, Trials and Deals
3 August 2026
2026 Kindler epidermolysis bullosa indication strategy covering epidemiology, FERMT1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Chronic granulomatous disease-associated colitis Indication Strategy Report 2026: NADPH oxidase, Trials and Deals
3 August 2026
2026 Chronic granulomatous disease-associated colitis indication strategy covering epidemiology, NADPH oxidase biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Epidermolysis bullosa simplex Indication Strategy Report 2026: KRT14, Trials and Deals
3 August 2026
2026 Epidermolysis bullosa simplex indication strategy covering epidemiology, KRT14 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
IPEX-associated enteropathy Indication Strategy Report 2026: FOXP3, Trials and Deals
3 August 2026
2026 IPEX-associated enteropathy indication strategy covering epidemiology, FOXP3 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Trichohepatoenteric syndrome Indication Strategy Report 2026: TTC37, Trials and Deals
3 August 2026
2026 Trichohepatoenteric syndrome indication strategy covering epidemiology, TTC37 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Congenital tufting enteropathy Indication Strategy Report 2026: EPCAM, Trials and Deals
3 August 2026
2026 Congenital tufting enteropathy indication strategy covering epidemiology, EPCAM biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Cronkhite-Canada syndrome Indication Strategy Report 2026: IL-6, Trials and Deals
3 August 2026
2026 Cronkhite-Canada syndrome indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Familial adenomatous polyposis Indication Strategy Report 2026: APC, Trials and Deals
3 August 2026
2026 Familial adenomatous polyposis indication strategy covering epidemiology, APC biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
MUTYH-associated polyposis Indication Strategy Report 2026: MUTYH, Trials and Deals
3 August 2026
2026 MUTYH-associated polyposis indication strategy covering epidemiology, MUTYH biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Juvenile polyposis syndrome Indication Strategy Report 2026: SMAD4, Trials and Deals
3 August 2026
2026 Juvenile polyposis syndrome indication strategy covering epidemiology, SMAD4 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Cowden syndrome Indication Strategy Report 2026: PTEN, Trials and Deals
3 August 2026
2026 Cowden syndrome indication strategy covering epidemiology, PTEN biology, active trials, transactions, unmet need, competition and market attractiveness.